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Abstract
Background: An increasing number of precision oncology programmes are being launched world-wide. To support
this development, we present the Cancer Variant Explorer (CVE), an R package with an interactive Shiny web browser
interface.
Results: Leveraging Oncotator and the Drug Gene Interaction Database, CVE offers exploration of variants within
single or multiple tumour exomes to identify drivers, resistance mechanisms and to assess druggability. We present
example applications including the analysis of an individual patient and a cohort-wide study, and provide a first
extension of CVE by adding a tumour-specific co-expression network.
Conclusions: The CVE package allows interactive variant prioritisation to expedite the analysis of cancer sequencing
studies. Our framework also includes the prioritisation of druggable targets, allows exploratory analysis of tissue
specific networks and is extendable for specific applications by virtue of its modular design. We encourage the use of
CVE within translational research studies and molecular tumour boards. The CVE package is available via Bioconductor
(http://bioconductor.org/packages/CVE/).
Keywords: Cancer variant explorer, Melanoma, Prioritization, Personalized oncology, WGCNA, Co-expression
network, TCGA, Molecular tumor board
Background
The majority of cancers are believed to be driven by
somatically acquired genomic alterations that converge
on cancer pathways. The advent of cost-effective, high-
throughput sequencing technologies has enabled the sys-
tematic cataloging of genomic landscapes of more than
50 tumour entities through national and international
projects e.g. The Cancer Genome Atlas (TCGA, [1]) and
the International Cancer Genome Consortium (ICGC,
[2]). For every entity, recurrent point mutations, deletions,
insertions, translocations and potential new treatment
targets were revealed. Pan-cancer analyses have further
helped to relate these findings across tumours [3]. In addi-
tion, sequencing studies have investigated intratumoural
heterogeneity and disease evolution [4, 5]. Meanwhile,
analysis of circulating tumour DNA (ctDNA) success-
fully enabled non-invasive monitoring of the evolution of
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different tumour clones and treatment resistance over the
course of the disease [6–9]. This convergence of discov-
ery, technology and therapeutic development has created
an opportunity to test whether systematic knowledge of
genomic information can successfully guide targeted ther-
apy and improve patient outcomes (reviewed in [10, 11]).
Owing to the decreasing costs of sequencing for rou-
tine diagnostics in clinical oncology [12], an increasing
number of cancer centres are switching from sequencing
panels of recurrent hotspot mutations to exome sequenc-
ing (approaches reviewed in [13]) in search of targetable
genetic variants. Here, variant prioritisation remains one
of the biggest obstacles because tumour genomes harbour
hundreds to hundreds of thousands of somatic muta-
tions [3]. Variant prioritisation in this context describes
the process of somatic mutation annotation and subse-
quent contrasting of evidence to identify ’known driver
variants’ and ’likely somatic driver variants’. This includes
cancer genes mutated at high frequency, although many
more are found to be mutated infrequently. The obser-
vation that known cancer driver gene mutations occur
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at low frequencies in some tumour entities (e.g. only 5%
of melanomas harbour hot-spot IDH1 mutations) sug-
gests that many drivers may yet remain undiscovered due
to limited cohort sizes [14]. For variants without prior
functional analyses related to cancer, a plethora of com-
putational approaches predicting their functional impact
has been developed in recent years. In addition, databases
of somatic mutations in cancer are at hand (e.g. COSMIC
database [15]).
Precision oncology seeks to leverage this molecular
information to improve patient treatment. This is a highly
collaborative effort and omics-driven therapeutic deci-
sions are being made in molecular tumour boards con-
sisting of physicians, bioinformaticians and biologists.
A number of web applications have been developed
to facilitate interactive prioritisation of variants [16–20]
(Additional file 1: Table S1). However, to our knowledge,
none is purpose-built for precision oncology, enables
functional extension (through open-source code) and
includes ‘druggability’ information about the prioritised
mutated genes.
We developed CVE, the Cancer Variant Explorer, to
provide an interactive and flexible application for vari-
ant prioritisation to support genomics-driven decision-
making. To show the functionality of CVE, we applied
it in a single colorectal cancer patient (as a ’molecular
tumour board’ example), as well as in a cohort study of 93
BRAF-wt/RAS-wt melanomas, where druggable targets
are poorly understood.
Implementation
Overview of CVE workflow
Cancer Variant Explorer (CVE) was created using the
Shiny web application framework for the R programming
language (shiny.rstudio.com), combining the high func-
tionality of R with a concise visualisation of the variant
prioritisation process (see Fig. 1 for screenshot of the
application interface). We supply the Shiny application
Fig. 1 Screenshot of CVE Shiny app. After loading the CVE package, the Shiny app can be started with the function openCVE
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CVE in the form of a Bioconductor R package to guaran-
tee long-term accessibility and maintenance. The steps of
the CVE core workflow to facilitate variant prioritisation
are: (i) variant annotation usingOncotator; (ii) exploration
of variant annotations; and (iii) assessment of druggabil-
ity using the Drug Gene Interaction database (DGiDb).
A graphical abstract of the CVE workflow is depicted
in Fig. 2. In the following implementation sections, the
individual steps of CVEs are described in more detail. A
step-by-step tutorial on the usage of CVE is also included
within the Bioconductor vignette.
Annotation of variants using Oncotator
The input file for CVE is a comma-separated (csv) file of
the format displayed in Additional file 2: Table S2. Before
running the interactive CVE application the variants are
annotated with the recently released Oncotator Variant
Annotation tool summarising variant-centric information
Fig. 2 Graphical abstract of CVE workflow. Variants of interest identified in high-throughput sequencing cancer studies are annotated using the
Oncotator Variant Annotation tool. Using this annotation, we developed an interactive web application for variant prioritisation named Cancer
Variant Explorer (CVE). Prioritisation is based on known germline and cancer variants, DNA repair genes and functional prediction scores. Exploration
of the tumour-specific pathway context is facilitated using co-expression modules generated from publicly available transcriptome data. Finally
druggability of prioritised variants are assessed using the Drug Gene Interaction Database (DGIdb)
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from 14 different publicly available resources relevant for
cancer researchers [21]. The Oncotator data sources used
are summarised in Table 1. The Oncotator annotation can
be retrieved using a function provided in the CVE pack-
age. By leveraging the Oncotator resource aggregation
platform, the annotations used in CVE remain updated
and flexible to the incorporation of additional annotations
in future.
Exploration of variant annotation
After launching the interactive CVE application (within
R, RStudio or by opening a web browser page, if running
CVE on a server), the interactive prioritisation begins with
the exploration of the Oncotator annotation. The ’func-
tional consequence’ annotation from GENCODE and
UniProt classifies the variant into protein changing and
non-protein changing as well as into single nucleotide
(SNP), double nucleotide polymorphism (DNP) and dele-
tion (DEL). The COSMIC database annotation denotes
whether a variant has been found previously in human
cancers, and the 1000 Genomes project data denotes
whether a variant has been found in germline samples.
The workflow aims to identify somatic driver variants,
therefore we would have more confidence in protein
changing variants that are recurrently mutated in cancer
and that are unlikely to be germline variants. In addition
information is provided as to whether a variant is in a
known DNA repair gene. Variants affecting DNA repair
genes are of particular therapeutic importance in can-
cer (and may predict sensitivity or resistance to a given
treatment).
Additional information on the predicted functional
impact of each variant is also included, providing lower
priority evidence to predict ’possible driver mutations’ in
lower frequency variants. This additional information is
collated from an increasing list of variant effect prediction
algorithms. New algorithms are continuously added to the
dbNSFP database, these are also included and updated in
the Oncotator annotation.
Table 1 Oncotator data sources used in workflow
Annotation category Resource Comments
Genomic GENCODE Variant classification and
mapping to gene
Human DNA
Repair Genes
Curated list from [40]
Protein UniProt Protein-specific
annotation
dbNSFP Conservation and
prediction scores
Cancer variant COSMIC Catalogue of Somatic
Mutations in Cancer
Non-cancer variant 1000 Genomes
Project
Germline SNVs
The prediction algorithms primarily exploit the rea-
soning that more deleterious gene regions have fewer
observed substitutions across species due to tighter evolu-
tionary constrains (i.e. conservation-based algorithms) or
the different physico-chemical properties of amino acids
and the corresponding three-dimensional protein struc-
ture (i.e. functional prediction algorithms). In addition,
ensembl scores combining different approaches have been
developed (e.g. CADD [22]). For more information about
the individual algorithm, see http://portals.broadinstitute.
org/oncotator/help/.
Of note, CVE does neither benchmark the scores of
the functional prediction algorithms, nor tries to derive
the best score. Instead, it displays the heterogeneity of
predication based on the rankscores of the 18 algorithms
in the current build of the dbNSFP database (Table 2).
Rankscores are given a value between 0 and 1, where 1
indicates the highest rank among the 87,347,043 possible
non-synonymous single-nucleotide variants in the human
genome. CVE depicts algorithms with similar rankscores
for a set of variants by means of a heatmap of the consen-
sus indices derived by consensus clustering [23]. The con-
sensus clustering methodology is illustrated in Additional
file 3: Figure S1 and the combination score is explained
below. However, the user of CVE can choose to use the
ranks for one particular algorithm, resembling one cluster
of scores, or the combination score.
Table 2 Mutation effect prediction algorithms in dbNSFP
database. Assignment to a category was made based on their
main working principle
Score name Category
1 PhastCons100way_vertebrate conservation
2 PhastCons46way_placental conservation
3 PhastCons46way_primate conservation
4 PhyloP100way_vertebrate conservation
5 PhyloP46way_placental conservation
6 PhyloP46way_primate conservation
7 SiPhy_29way_logOdds conservation
8 GERP++ conservation
9 FATHMM function prediction
10 LRT function prediction
11 MutationAssessor function prediction
12 MutationTaster function prediction
13 Polyphen2_HDIV function prediction
14 Polyphen2_HVAR function prediction
15 SIFT function prediction
16 LR ensemble score
17 RadialSVM ensemble score
18 CADD ensemble score
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We propose that the maximum useful information can
be derived from the dbNSFP combination score c for
the rankscore of algorithm i in cluster j determined by
consensus clustering
c =
m∑
j=1
yj with yj =
{
xij if xij ≥ 0.75
0 if xij < 0.75
(1)
where xij is the rankscore of algorithm i in cluster j and
xij the mean rankscore of algorithm cluster j. xij is only
added to c if there is significant evidence for the variant in
algorithm cluster j, defined by amean rankscore belonging
to the upper quartile of rankscores.
Assessment of druggability
The final step required to guide precision cancer medicine
is the assessment of the druggability of candidate vari-
ants. The Drug-Gene Interaction database (DGIdb, [24])
offers a comprehensive collection of drug-gene interac-
tions from six sources: PharmGKB [25]; The Therapeu-
tic Target Database (TTD) [26]; the ’targeted agents in
lung cancer’ (TALC) publication [27]; the ’trends in the
exploitation of novel drug targets’ (TEND) publication
[28]; and My Cancer Genome [29]. Within the CVE
workflow we retrieve data from TEND and My Can-
cer Genome, because both sources are expert-curated
and comprise data from multiple tumour types. Within
the TEND data, we only used antineoplastic agents (for
detailed description of drug classes summarized in this
group, see supplemental material of [24]). Of note, a gene
will be deemed druggable in CVE independent of the
tumour entity for which the drug was approved. This is
consistent with the increasing trend of administering tar-
geted therapies "off-label", after progression on standard
of care treatment. However, it should be made clear that
treatment efficacy in a specific molecular subtype can-
not be accurately predicted in the absence of clinical trial
data. CVE accesses the DGIdb data via the application
programming interface (API). This way, a local installation
of the database is not required and the entries retrieved
include the most up-to-date annotations.
Cohort case study in melanoma
BRAF and RAS hotspot mutations occur frequently in
cutaneousmelanomas and can be targeted with BRAF and
MEK inhibitors, respectively. However, ≈ 27% of tumours
do not harbour BRAF or RAS hotspot mutations and
are lacking suitable targeted treatment options. To this
end, we gathered a case study from TCGA data with the
aim to identify drivers and putatively druggable variants
in BRAF-wt/RAS-wt melanomas. 93 of the 345 patients
could be classified as BRAF-wt/RAS-wt according to the
TCGA definition [30]. A ’maf ’ file containing the sin-
gle nucleotide variant (SNV) data of TCGA melanoma
patients were downloaded from the TCGA data por-
tal at August 13th, 2015. A list of the TCGA barcodes
and the BRAF/RAS classification are appended in the
Additional file 4.
Generation of melanoma-specific co-expression network
A tutorial describing the generation of a weighted gene co-
expression network analysis (WGCNA) from The Cancer
Genome Atlas (TCGA) RNA-seq data using the WGCNA
R package developed by Langfelder and Horvarth [31] is
included as a vignette in the Bioconductor page of CVE.
To construct the melanoma-specific co-expression net-
work, publicly available RNA-sequencing data from 472
melanoma samples were downloaded from the TCGA
(The Cancer Genome Atlas) on December 14th, 2015.
Curated metadata was obtained for a subset of 332
patients from themost recent TCGApublication [30]. The
study set included both primary and metastatic tumour
samples, as included in the original TCGA publication.
For reproducibility, the TCGA barcodes of the samples
can be found in the Additional file 5.
To identify co-expression modules in the 472 melanoma
patients, genes were next clustered based on the dis-
similarity measure, where branches of the dendrogram
correspond to modules. The gene dendrogram obtained
by average linkage hierarchical clustering is depicted
in Fig. 3a. Ultimately, gene co-expression modules are
detected by applying a branch cutting method. Here,
we employed the dynamic branch cut method devel-
oped by Langfelder and colleagues [32], because constant
height cutoffs perform sub-optimally on complex den-
drograms. By applying WGCNA in this way to the 472
TCGA melanoma samples we identified 41 co-expression
modules. All other genes that were not significantly co-
expressed within one of these modules are summarized
in module 0 for subsequent analysis (grey colour at 2
’o’clock in the circular eigengene phylogram; Fig. 3b). The
relationship between the identified co-expression mod-
ules can be visualized by a dendrogram of their eigengenes
(Fig. 3b). The module eigengene is defined as the first
principal component of its expression matrix. Module
eigengenes were highly correlated with the gene that had
the highest intramodular connectivity [33]. An advantage
of co-expression network analysis is the possibility to inte-
grate external information (such as clinical features). At
the lowest hierarchical level, gene significance (GS) mea-
sures can be defined as the statistical significance (i.e.
p-value, pi) between the i-th node profile (gene) xi and the
sample trait T : GSi = −log pi.
Module significance in turn can be determined as
the average absolute gene significance measure. This
conceptual framework can be adapted to any research
question. For the exploration of variants in a melanoma-
specific pathway context, five GS measures were used: (i)
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Fig. 3Weighted co-expression network analysis. a Gene dendrogram obtained by average linkage hierarchical clustering of TCGA melanoma
RNA-seq data (n=472). Colour bar under the plot shows the module assignment determined by the Dynamic Tree Cut algorithm. b Eigengene
phylogram of the 41 co-expression modules and module 0 (grey dot at 2 o’clock), which contains all genes not included in any of the co-expression
modules. c Graphical summary of the module significance for the 5 gene significance measures as displayed in Cancer Variant Explorer. Modules are
named according to the most significant GO term in the enrichment analysis with less than 100 genes per term (to exclude uninformative,
high-level GO terms). Barplots show the average absolute gene significance measure per module, i.e. the module significance
lymphocyte score; (ii) survival association; (iii) UV signa-
ture; (iv) comparative analysis of primary and metastatic
tumours; and (v) vemurafenib resistance. The first 4 GS
measures were derived from clinical metadata of the
TCGA samples. The samples were dichotomized accord-
ing to lymphocyte score (histopathological quantification
of lymphocyte infiltration in melanomas), the presence of
a UV signature as defined by Brash and coworkers [34], or
primary vs. metastatic tumours and comparative statistics
performed (unpaired two-sided Welch’s t-test). The effect
size was the absolute difference in average expression
between the groups. For survival analysis, post-accession
survival was used as a clinical endpoint in univariate cox
proportional hazard models, with the hazard ratio as the
effect size. Lastly, to identify variant genes contributing
to vemurafenib resistance on the transcriptional level, we
derived GS measures using a cell-line dataset recently
published by Parmenter and colleagues [35].
To enable a high-level interpretation of the dendrogram
of module eigengenes, gene ontology (GO) enrichment
analysis was performed for the module genes using the
GOstats R package [36]. Modules were named accord-
ing to the most informative GO term with less than 100
genes per term. The module membership is defined as
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Kq = |cor(xi,Eq)| where xi is the profile of gene i and
Eq is the eigengene of module q. Based on this defini-
tion, K describes how closely related gene i is to module
q. Figure 3c illustrates the graphical summary of mod-
ule significance for five melanoma relevant parameters
(GS measures). This plot helps to guide the interpre-
tation of variants on the level of co-expression mod-
ules in CVE. A cluster of 9 co-expression modules was
significantly associated with the lymphocyte infiltration
score. Intriguingly, all 6 survival (post-accession) associ-
ated co-expression modules were also significantly asso-
ciated with the lymphocyte score. In addition, 4 modules
were associated with tumour relapse (epidermal cell dif-
ferentiation, odontogenesis, fatty acid metabolic process,
collagen catabolic process). Interestingly, on the tran-
scriptional level, vemurafenib resistance in this cell line
derived data [35] is defined by differences in multiple co-
expression modules, suggesting either a broad spectrum
of changes or a lack of a clear relationship between the cell
line study and our tumour tissue-derived co-expression
networks.
Together these data provide a framework for the
tumour-specific annotation of novel ’putative events’ in
melanoma.
Results
The core implementation of the CVE Shiny app comprises
four interactive tabs (i) Annotation, (ii) Prioritisation, (iii)
Top table and (iv) Druggability. In the following sections
we describe the settings and results for a cohort case study
in 93 BRAF-wt/RAS-wt melanomas, as an example imple-
mentation for variant exploration using CVE. In addition,
we present a first extension of CVE functionality for the
exploration of variants in melanoma using a tumour-type
specific co-expression network (see Implementation for
details).
Annotation tab
The CVE annotation tab displays a total of 1084 protein-
changing single-nucleotide variants (SNVs) from the
93-patient melanoma cohort. The Annotation tab also
displays the variant classification (e.g. missense, nonsense,
frame-shift etc.) as well as a heatmap of the clusters of pre-
diction algorithms for the dataset. As shown in Additional
file 3: Figure S1, four algorithm clusters were identified
for the melanoma cohort. Based on the heatmap, the user
has the option to either select a single prediction algo-
rithm resembling the information of one algorithm cluster
or the proposed dbNSFP combination score (that aims
to collapse redundant information). For users unfamiliar
with the specific implementations underlying each algo-
rithm, we recommend using the dbNSFP combination
score (which was used for prioritisation in our 93-patient
melanoma case study).
Prioritisation tab
The proritisation tab is central to the interactive pro-
cess of identifying variants of interest. Firstly, common
germline variants identified by the 1000 Genomes project
can be filtered from further analysis. In the melanoma
case study, 67 of the 1084 protein changing SNVs were
possible germline variants (a common artifact in many
somatic mutation calling pipelines). To exclude all possi-
ble germline variants a filter ’check-box’ located on the
left side panel can be applied, alternatively a threshold can
be set to include variants present at low frequencies in
germline data sets (e.g. DNMT3A R882 [37]), depending
on the required stringency. Secondly, variants overlap-
ping COSMIC annotations are displayed, to allow the
prioritisation of recurrently mutated sites that are ’likely
driver events’. In the case study there were 167 over-
lapping COSMIC variants (i.e. mutated in other cancer
samples), a subset of which were frequently altered in can-
cer. Here, depending on the aim of the analysis all of the
167 overlapping COSMIC variants can be included for
further analysis by applying a filter located on the left
side panel. Similarly, mutations in DNA damage repair
genes can be included in further analysis using a fil-
ter located on the left panel of CVE. Finally, the user
has the option to interactively choose variant effect pre-
diction algorithms and cutoff thresholds for functional
predictions (please see the Implementation section for
detailed descriptions of the dbNSFP combination score).
This step summarises the predictions that a given vari-
ant has a functional impact, using either individual variant
effect prediction tools or the combination score that we
recommend (see Implementation for details of this con-
sensus clustering). We suggest the use of cutoff thresholds
above 1, as this indicates evidence in at least 2 algo-
rithm clusters. For users familiar with the functional pre-
diction algorithms, CVE also offers the functionality to
choose individual scores. In the case study, we aimed to
obtain a list of ≈ 50-150 prioritised variants suitable for
targeted panel sequencing and choose a dbNSFP com-
bination score cutoff of 2. This led to 143 variants in
the melanoma case-study. Plots illustrating the number
of variants at a chosen cutoff together with annota-
tions for 1000 Genomes, COSMIC and DDR gene vari-
ants are displayed within the prioritisation tab at this
stage.
Top table tab
A table of the prioritised variants shortlisted up to this
point can be accessed in the next tab of the CVE applica-
tion. For streamlined data handling, this top table can also
be downloaded as a tab-separated file using the down-
load button in the sidebar (for subsequent visualization
in spreadsheet software or downstream analysis). The
columns of the top table summarize:
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• gene: gene symbol
• protein change: location of amino acid change in
protein
• type: SNV, dinucleotide substitution (DNP), deletion
(DEL) or insertion (INS)
• classification: functional consequence annotation
from GENCODE
• score: (rank)score of the mutational effect prediction
algorithm selected
• COSMIC entity: number of mutations identified per
tumour entity in the COSMIC database
Druggability tab
Using annotations from the Drug-Gene Interaction
database (DGIdb) CVE also allows exploration of poten-
tially druggable targets within a given dataset. To show the
full spectrum of evidence for or against a druggable vari-
ant in the melanoma case study, no dbNSFP combination
score cutoff was initially set. Table 3 summarises all drug-
gene interactions available for all 1084 SNVs. However,
as previously stated, the user of CVE has full flexibil-
ity to adjust these settings at any point of the analysis
within the CVE application. The highest confidence vari-
ants would be those annotated to be recurrently mutated
in the COSMIC database and/or with additional weight
for variants with a high dbNSFP score. In contrast, the
efficacy of a drug against a mutated gene is less likely
where there is little supporting evidence of the mutation
having a functional impact (e.g. from COSMIC annota-
tions or dbNSFP scores). Altogether, putatively druggable
variants were found in≈ 25% (23 of 93) of BRAF-wt/RAS-
wtmelanoma patients, with 6 patients having two possible
drug-gene combinations. The largest drug class identified
for this cohort are tyrosine kinase inhibitors that could be
potentially used in ≈ 15% of cases (14 of 93).
CVE extension: Melanoma co-expression network tab
The four tabs in the core implementation of CVE can
be applied to all tumor entities. To illustrate the func-
tionality and flexibility of an open-source R package, we
developed a first extension to explore the variant genes
in a melanoma-specific co-expression network. A vignette
describing the generation of the co-expression network
using the WGCNA R package [31] can be found on the
Bioconductor site (and is outlined in the Implementation
section).
Figure 3c summarises the number of variant genes per
co-expression module (# variants column) for the follow-
ing prioritisation settings: (i) dbNSFP combination score
cutoff >2; (ii) exclude 1000 Genomes Project variants;
and (iii) include all COSMIC variants. Of the resulting
278 variants, 122 occurred in genes that were part of
the top 5000 most variant genes of the co-expression
network (consistent with a functional role for these genes
in melanoma biology). A total of 24 mutated genes fall
into the cluster of co-expression modules associated with
the lymphocyte infiltration score and overall survival.
To further explore an individual module of interest, CVE
generates a plot of the module membership over the
p-value of the respective gene significance measure (e.g.
lymphocyte score; Additional file 6: Figure S2). As a third
dimension, we weighted the dot-size according to the
effect size of a given gene to the module. Additional file 6:
Figure S2 depicts the exploration of co-expression mod-
ule 3 (leukocyte activation involved in immune response),
a module that was both significantly associated with the
Table 3 Druggability case study. The protein coding change for variants are shown separated by a colon after the gene symbol.
Databases listing the drug-gene interaction are abbreviated (T=TEND, M = My Cancer Genome)
Variant Patient id dbNSFP score COSMIC Drug Database
EPHA2:p.S790F 26, 52 1.768360 tyrosine kinase inhibitor T
EPHA2:p.E607K 48, 87 1.737764 tyrosine kinase inhibitor T
GART:p.S635F 50, 56 0 folate antimetabolite T
KDR:p.S1100F 16, 45, 75 2.679266 tyrosine kinase inhibitor T & M
KIT:p.K642E 3, 27, 31, 70 2.454228 yes tyrosine kinase inhibitor T & M
KIT:p.V559A 25, 38 2.650527 yes tyrosine kinase inhibitor T & M
LHCGR:p.E206K 44, 45 0.77191 yes GnRH agonist T
MS4A1:p.G115E 52, 79 0 anti-CD20 antibody T & M
MTOR:p.A1105T 65, 66 0.8908875 yes mTOR inhibitor T & M
PDCD1:p.E211K 34, 51 0 anti-PD1 antibody M
PIK3C2G:p.E1231K 23, 48 0 PI3K inhibitor M
PRKCB:p.R361Q 44, 50 0.959385 protein kinase C inhibitor M
ROS1:p.P1539S 20, 26 0 tyrosine kinase inhibitor M
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lymphocyte score and post-accession survival. In line
with the GO term, all variant genes in this module were
involved in leukocyte regulation, with the exception of
one multidrug resistance gene (ABCB1). The visualisa-
tion of variant genes within the co-expression module
enables us to identify variants with a very high module
membership, effect size or p-value as well as signifi-
cant associations with the remaining gene significance
measures for which a total module significance was not
reached. For example, in addition to a significant associ-
ation with lymphocyte score and post-accession survival,
FMO3 is associated with relapse and ADAMDEC1 and
ABCB1 with the UV mutation signature (Additional file
6: Figure S2). Hence, this part of the workflow allows us
to provide a biological context for variants with likely
functional impacts, expediting both further biological
and potentially clinical studies.
Discussion
In recent years, Precision Cancer Medicine has devel-
oped from a mere buzz word into a framework for
clinical decision-making at several comprehensive can-
cer centres world-wide. On the one hand, cost-effective
targeted sequencing approaches are used to assess the
ever-increasing number of known cancer drivers often
prospectively within clinical trials. On the other hand,
genome-wide analyses (i.e. exome sequencing) help to
unveil this increasing list, mainly through retrospective
comparisons. As more and more data are generated, clin-
ical utility increases, but so does the complexity in data
analysis.
A number of web applications have been developed to
facilitate interactive prioritisation of variants (Additional
file 1: Table S1). BrowseVCF is a comprehensive open
source web application based on Python [16], enabling the
exploration of VCF files, but requires variant annotation
upstream of the tool. Database.bio is another web appli-
cation for variant prioritisation [17]. However, at the time
of writing, neither the tool website nor the supplemental
material of the manuscript were available online. The web
application Exome Variation Analyzer (EVA) offers multi-
ple modules for variant prioritisation using the commer-
cial IntegraGen annotation [18], but at the time of writing
this tool was also not available online. gNOME is a com-
prehensive web application, including the functionality to
explore variant genes within pathways (GO, KEGG). How-
ever, no druggability information about the variant gene
is available. Lastly, SNVerGUI is a Java application avail-
able for multiple platforms, focusing on the exploration
of BAM/SAM files, but does not offer a cancer-specific
annotation [20]. To our knowledge, no freely available
web application is purpose-built for precision oncology
and comprises druggability information about prioritised,
mutated genes within a single framework. In addition, we
believe that in the long run, collaborative efforts using
open source programming environments such as R will
be needed to effectively translate new information for
specific diagnostic or research questions.
Arguably the most challenging part of any tool for
Precision Cancer Medicine is variant prioritisation. Here,
variant effect prediction algorithms are an integral
part, however the incorporation of additional knowledge
databases are crucial to fully support clinical interpreta-
tion of cancer genomic data. At this point interactivity and
flexibility are key, to allow different criteria to be applied
for variant filtering, depending on the scientific question
(e.g. druggability in Oncology trials or target discovery
studies for drug development). We developed a Shiny
web application based on the R statistical environment
enabling end users (such as biologists and physicians) to
interactively apply different cutoffs and filters.
The data sources implemented in this version of
CVE include the comprehensive cancer variant anno-
tation tool Oncotator, germline annotations from the
1000 Genomes Project, known cancer-associated vari-
ants (COSMIC database), known DNA repair genes and
known cancer driver genes. Ultimately, genomics-driven
oncology aims at identifying druggable variants, therefore
we also include functionality to explore expert-curated
sources of drug-gene interactions (TEND and My Cancer
Genome, using the DGiDb). Due to the simple program-
ming framework of the application, additional filters and
datasets can be implemented in a very short time. This
flexibility in adding parameters or data sources to the pri-
oritisation workflow is very valuable and not offered by
commercial tools for variant prioritisation (e.g. Ingenuity
Variant Analysis). To ensure reproducibility, a spread-
sheet with the prioritised variants can be downloaded
from the side panel of CVE (including a list of the filters
and thresholds applied).
The aforementioned framework for variant prioritisa-
tion has the advantage to work independently of the
tumour entity. However, this variant-centric annotation
focuses on already known cancer drivers and variants,
limiting the potential to identify less well characterised
variants. A variant prioritisation workflow in the con-
text of clinical trials or translational research should
also highlight potentially functional variants that have
not been extensively characterized before. In addition,
some mutated genes are druggable targets in one tumour
entity but not in other tumour types (e.g. vemurafenib
is ineffective in BRAF V600 mutant colorectal cancers
[38]). Therefore, we aimed to explore variants in the
tumour-specific pathway context using transcriptomic
data. To our knowledge, the current work is the first
to employ weighted co-expression network analysis to
explore cancer variants in the tumour-specific pathway
context. Prerequisite was a large tumour study sample
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with comprehensive clinico-pathological metadata. Here,
all tumour data made publicly available by the TCGA ful-
fills this requirement. In this work, a melanoma-specific
co-expression network was built based on 472 patients.
Next, individual variants and co-expression modules were
related to sample traits. In this way we could assess asso-
ciations with (i) the lymphocyte score, (ii) recurrence, (iii)
UV signature and (iv) post-accession survival, using the
TCGA metadata. In line with the recent transcriptomic
characterization of cutaneous melanomas by the TCGA
[30], in which the authors describe an immune gene
expression subclass associated with an improved patient
survival, a cluster of 6 co-expression modules was signif-
icantly associated with the lymphocyte infiltration score
and in parallel with post-accession survival. In addition, 4
modules were associated with tumour relapse. By explo-
ration of candidate variants in the melanoma-specific co-
expression modules, previously unknown variants could
be associated with different GSmeasures. These new find-
ings support the utility of weighted co-expression network
analysis for variant prioritisation and provide a starting
point for future studies.
The Cancer Variant Explorer, is an interactive, iter-
ative and flexible application based on the R pro-
gramming environment. Using the comprehensive data
from the Oncotator Cancer Variant Annotation tool,
CVE enables project-tailored variant prioritisation using
cancer-relevant databases. Extending current workflows
by adding another level of biology it offers the explo-
ration of variant genes in tumour-specific co-expression
modules. CVE was applied in a case study of melanoma
patients, revealing potentially druggable targets and high-
lighting genes that have not previously been linked to
melanoma and were associated with clinically relevant
melanoma gene expression networks.
Conclusions
Precision Cancer Medicine has great promise to improve
the treatment of cancer patients, but several obstacles
have to be overcome to increase the success rates of
personalised treatments. It will be crucial to more com-
prehensively identify mechanisms of treatment resistance,
especially within the context of the clonal make-up of a
tumour. Likewise, robust pharmacogenomic analysis are
needed to validate the druggability of candidate vari-
ants. In addition, while targeting specific SNVs has been
proven successful in some cancers, pan-cancer analy-
sis revealed that not all tumour entities are primarily
driven by point mutations, with copy number changes
dominating in many cancer types (e.g. ovarian cancer or
head and neck squamous cell carcinoma, [39]). Hence,
methods for prioritising gene targets within copy number
altered regions and integrating these with SNV informa-
tion may increase the proportion of patients who could
benefit from targeted therapies. Ultimately, as genomics-
driven oncology is complementary to other therapeu-
tic approaches in oncology, combinations of different
treatment approaches are emerging as the next step
to improve response rates (such as combinations with
immunotherapy, targeting of the tumour microenviron-
ment or cell-based treatments [10]). In the long run, the
integration of clinical, pathological and genomic anal-
ysis in the context of molecular tumour boards also
demands a seamless integration of variant prioritisa-
tion tools into hospital IT infrastructures. Given the
flexibility of open-source programming structures and
web browser implementations, interactive variant pri-
oritisation tools (such as the CVE implementation in
Shiny) have the potential to be at the forefront of these
developments.
Availability and requirements
Project name: Cancer Variant Explorer (CVE)
Project home page: http://bioconductor.org/packages/
CVE. CVE will be continuously updated. To work with the
latest version, please refer to the development branch in
Bioconductor.
Operating system(s): Platform independent
Programming language: R
Other requirements: R 3.3 or higher, R packages: shiny,
ConsensusClusterPlus, RColorBrewer, gplots, plyr, ggplot2,
jsonlite, ape, WGCNA, RTCGAToolbox
License: GNU GPL-3
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Additional file 1: Table S1. Comparison of tools for interactive variant
prioritisation applicable to cancer exomes. (PDF 72 kb)
Additional file 2: Table S2. Showing the input variant format of CVE.
(PDF 69 kb)
Additional file 3: Figure S1. Consensus clustering of dbNSFP rankscores
for 1084 protein-changing variants revealed in the case study. Consensus
clustering of dbNSFP rankscores for 1084 protein-changing variants
identified in the case study. To determine the most meaningful number of
clusters of prediction scores, we first assess the consensus CDFs (Figure
S1A) and the relative change in the area under the CDF curve ((k),
Fig. S1B). Here, (k) did not increase markedly at more than 5 clusters.
Next, using the heatmap of the hierarchical clustering of consensus
indexes for the different cluster numbers (Figure S1C), we can question
the plausibility of clusters in light of the different prediction score
categories. This approach revealed that a fifth cluster created another
subcluster in the conservation scores only, indicating that 4 clusters could
be a more systematic choice. (A) Plot of cumulative distribution functions
(CDFs) corresponding to the consensus matrices in the range between 2
and 6 clusters. (B) Relative change in the area under the CDF curve (k). (C)
Heatmap illustrating the hierarchical clustering of consensus index for 4
clusters of prediction algorithms based on 100 permutations and
resampling of 80% of the algorithms and 80% of the variants. Functions
provided by the ConsensusClusterPlus R package were used to perform the
analysis [41]. (PDF 325 kb)
Additional file 4: Table S3. Csv table listing the 345 TCGA barcodes of
melanoma SNV cohort with classification. (CSV 16 kb)
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Additional file 5: Table S4. Csv table listing the 472 TCGA barcodes of
melanoma RNA-seq cohort used for co-expression network analysis.
(CSV 50 kb)
Additional file 6: Figure S2. Exploration of prioritised variant genes
within co-expression modules from the case study. Exploration of
prioritised variant genes within co-expression module 3 (leukocyte
activation involved in immune response) for the 5 Gene Significance
measures. Module membership is defined as the correlation between the
gene profile and the eigengene of module 3. Dots are weighted according
to effect size. A p-value cutoff of <0.05 is indicated by the vertical dashed
line. A short description of the gene function is given. (PDF 20 kb)
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